Compare PGEN & VISN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | VISN |
|---|---|---|
| Founded | 1998 | 1976 |
| Country | United States | United States |
| Employees | 47 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2013 | 2013 |
| Metric | PGEN | VISN |
|---|---|---|
| Price | $7.70 | $6.48 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | $8.33 | ★ $21.00 |
| AVG Volume (30 Days) | 3.7M | ★ 8.2M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 641.01 |
| EPS | 0.03 | ★ 24.79 |
| Revenue | $230,981,000.00 | ★ $1,931,600,000.00 |
| Revenue This Year | $1,115.92 | $9.44 |
| Revenue Next Year | $81.04 | $5.91 |
| P/E Ratio | $258.83 | ★ $0.26 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.99 | $6.00 |
| 52 Week High | $8.04 | $19.91 |
| Indicator | PGEN | VISN |
|---|---|---|
| Relative Strength Index (RSI) | 64.70 | 29.91 |
| Support Level | $6.57 | $6.00 |
| Resistance Level | $7.72 | $12.59 |
| Average True Range (ATR) | 0.27 | 0.22 |
| MACD | 0.05 | 0.11 |
| Stochastic Oscillator | 76.41 | 56.94 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Vistance Networks Inc operates in the communications technology sector, providing solutions designed to support the delivery and management of communications services. It serves customers globally through teams involved in product development, implementation, and customer support. The company designs and develops network infrastructure and connectivity solutions focused on reliability and performance. Its offerings include intelligent networking technologies intended to support evolving communication requirements.